Table 4. Interpretation of serologic test results* for HBV infection
This web page is archived for historical purposes and is no longer being updated. Newer content is available at www.cdc.gov/std/treatment
Serologic marker | Interpretation | |||
---|---|---|---|---|
HBsAg† | Total anti-HBc§ | IgM¶ anti-HBc | Anti-HBs** | |
- | - | - | - | Never infected |
+†† | - | - | - | Early acute infection; transient (up to 18 days) after vaccination |
+ | + | + | - | Acute infection |
- | + | + | - | Acute resolving infection |
- | + | - | + | Recovered from past infection and immune |
+ | + | - | - | Chronic infection |
- | + | - | - | False positive (i.e., susceptible); past infection; “low-level” chronic infection§§; passive transfer to infant born to HBsAg-positive mother |
- | - | - | + | Immune if concentration is >10 mIU/mL,¶¶ passive transfer after HBIG administration |
* Symbol for negative test result, “–“; symbol for positive test result, “+”.
† Hepatitis B surface antigen.
§ Antibody to hepatitis B core antigen.
¶ Immunoglobulin M.
** Antibody to HBsAg.
†† To ensure that an HBsAg-positive test result is not a false positive, samples with repeatedly reactive HBsAg results should be tested with an FDA-cleared (and, if appropriate, neutralizing confirmatory) test.
§§ Persons positive for only anti-HBc are unlikely to be infectious except under unusual circumstances involving direct percutaneous exposure to large quantities of blood (e.g., blood transfusion and organ transplantation).
¶¶ Milli-International Units per milliliter.
- Page last reviewed: January 28, 2011 (archived document)
- Content source: